Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal epithelial cell barrier
- Molecular classification
- Other (cellular structure/system), Tight junction proteins (e.g., claudins, occludins, zonula occludens), Adherens junction proteins (e.g., cadherins), Desmosomal proteins (e.g., desmogleins, desmocollins), Mucins (secreted by goblet cells)
01
Overview
The intestinal epithelial cell barrier is a single-layer structure lining the gut, composed of various specialized epithelial cells joined by tight junctions, adherens junctions, and desmosomes. Its main role is to maintain selective permeability—allowing beneficial molecules like ions, nutrients, and water from the lumen into the body, while preventing the entry of pathogens, toxins, and antigens. It also interfaces with the immune system and the gut microbiota, regulating immune homeostasis and providing defense against external threats. Disruption of the barrier is implicated in numerous diseases ranging from gastrointestinal inflammation to metabolic and autoimmune disorders. While drugs target related pathways and components, the barrier itself is a multifaceted system and not a single molecular entity, limiting its direct druggability at present[1][2][3][4].
- Other names
- Intestinal epitheliumintestinal barriergastrointestinal epithelial barrier
02
Mechanism of action
Drugs may act by decreasing inflammation (which preserves barrier integrity), modulating tight junction proteins, or enhancing epithelial cell survival/regeneration[4].
03
Biological functions
Barrier function (prevents entry of microbes, toxins, antigens)Selective permeability (nutrient, ion, and water transport)Immune regulation (through interaction with underlying immune cells)Host-microbial interactionsCell renewal and wound healing
04
Disease associations
Inflammation (e.g., inflammatory bowel disease)Infection (intestinal pathogens)Autoimmune disease (e.g., extra-intestinal autoimmune disorders such as rheumatoid arthritis, multiple sclerosis)Metabolic disorders (e.g., obesity, diabetes)Cancer (colorectal cancer risk with chronic damage)
05
Safety considerations
Barrier disruption may increase risk of infection, inflammation, and systemic diseaseTherapeutic enhancement of barrier function must avoid excessive inhibition, which could impair necessary physiological absorption of nutrientsDrugs that damage barrier function (e.g., NSAIDs, certain chemotherapies/radiotherapies) pose substantial safety risks
06
Interacting drugs
Aminosalicylates
3 more in the full profile.
07
Biomarkers
Intestinal permeability assays (e.g., lactulose-to-mannitol ratio)Tight junction protein levels (occludin, claudin, ZO-1)Mucins (e.g., MUC2)Cytokine profiles (markers of inflammation)
Beyond the preview
Go deeper on Intestinal epithelial cell barrier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intestinal epithelial cell barrier.